Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.
Advertisement

Related Content

Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.
NPS Estimates Gattex Initial Market At $150 Million To $250 Million
NPS Estimates Gattex Initial Market At $150 Million To $250 Million
AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million
NPS Turns Attention To Teduglutide After Preos “Approvable” Letter
NPS Turns Attention To Teduglutide After Preos “Approvable” Letter
Preos “Approvable” Pending Additional Clinical Data, NPS Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS065761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel